昨晚美股Immuron大涨8倍，A股也有对标

Immuron Limited ("lmmuron") (ASX:IMC)
(NASDAQ:IMRN), is an Australian microbiome
biopharmaceutical company focused on developing andcommercializing orally delivered targeted polyclonal
antibodies for the treatment of inflammatory mediated andinfectious diseases. Immuron has а unique and safe
technology platform that enables a shorter developmenttherapeutic cycle. The Company currently markets and
sells Travelan for the prevention of Travelers‘ Diarrhea andits lead clinical candidate, IMM-124E, is in Phase lI clinicaltrials for Non-Alcoholic Steatohepatitis (NASH), SevereAlcoholic Hepatitis (SAH) and Pediatric Nonalcoholic FattyLiver Disease (NAFLD). Immuron‘s second clinical stageasset, IMM- 529, is targeting Clostridium difficile Infections(CDI). These products together with the Company‘s otherpreclinical immunotherapy pipeline products targeting immune-related diseases currently under development, willmeet a large unmet need in the global immunotherapy Immuron Limited(“lmmuron”)(ASX：IMC)
(纳斯达克 市场代码：IMRN)，是澳大利亚的一个微生物群。生物制药公司致力于开发和商业化口服靶向多克隆药物。用于治疗炎症介导和传染病的抗体。Immuron具有а的唯一性和安全性，使开发治疗周期更短的技术平台。该公司目前的市场和
销售用于预防旅行者腹泻的Travelan及其领先的临床候选产品imm-124 e，目前正在进行非酒精性脂肪性肝炎(NASH)、SevereAlcoholic肝炎(SAH)和小儿非酒精性脂肪肝(NAFLD)的临床试验。Immuron的第二个临床分期，imm-529，针对艰难梭菌感染(CDI)。这些产品和公司的其他临床前免疫治疗管道产品瞄准目前正在发展中的免疫相关疾病，将满足全球免疫治疗中大量未得到满足的需求。

众生药业 的子公司广东众生睿创生物科技有限公司也是做NASH的~